Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2019 ASCO Annual Meeting but not presented at the Meeting, can be found online only.
Utility of the Lung Immune Prognostic Index (LIPI) in prognostication and disease control prediction in advanced NSCLC patients treated with nivolumab.
Metastatic Non-Small Cell Lung Cancer
Lung Cancer—Non-Small Cell Metastatic
2019 ASCO Annual Meeting
J Clin Oncol 37, 2019 (suppl; abstr e20645)
Author(s): Juan Ruiz Bañobre, María C. Areses Manrique, Rosario García Campelo, Rafael Lopez, Francisco J. Afonso Afonso, Joaquín Casal Rubio, Sergio Vázquez Estévez, Cristina Azpitarte Raposeiras, Margarita Amenedo, Lucía Santomé, José Luis Fírvida Pérez, Joaquín Mosquera Martínez, Alexandra Cortegoso, Rocío Vilchez Simó, Gerardo Huidobro Vence, Natalia Fernández Núñez, Nazaret Quiroga Veiga, Jesús García Mata, Guillermo Alonso-Jáudenes Curbera, Urbano Anido Herranz; Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain; Complejo Hospitalario Universitario de Ourense, Ourense, Spain; Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain; Complejo Hospitalario Universitario de Santiago de Compostela, Santiago De Compostela, Spain; Complejo Hospitalario Universitario de Vigo, Vigo, Spain; Hospital Universitario Lucus Augusti, Lugo, Spain; Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Medical Oncology Dept. University Hospital A Coruña (CHUAC-SERGAS), A Coruña, Spain
Background: The lung immune prognostic index (LIPI) has been proposed as a new biomarker to select advanced non-small cell lung cancer (NSCLC) patients for anti-programmed cell death-1 or programmed death ligand 1 therapy. In this study, we investigate the prognostic and predictive utility of the LIPI in a multicentric nivolumab monotherapy-based cohort. Methods: 153 patients with available baseline LIPI were included. Survival estimates were calculated by the Kaplan-Meier method, and groups were compared with the log-rank test. The impact of the baseline LIPI on survival (PFS and OS), and DCR and ORR was assessed by Cox and logistic regression models respectively, adjusted for age, sex, ECOG-PS, smoking status, histology, TNM stage at diagnosis, presence of brain metastases and number of prior regimens. All p values were 2-sided, and those less than 0.05 were considered statistically significant. Results: 50.3% (n = 77) of the patients had a good (0 factors) LIPI, while 41.2% (n = 63) and 8.5% (n = 13) had intermediate (1 factor) and poor (2 factors) LIPI respectively. No significant differences were observed between the LIPI groups according to clinicopathologic characteristics. A high LIPI was significantly associated with poor OS in univariate (HR = 3.12, 95% CI 2.12 – 4.60; p < 0.0001) and multivariate (HR = 3.10, 95% CI 2.09 – 4.58; p < 0.0001) analyses. A high LIPI was associated with poor PFS (HR = 1.49, 95% CI 1.07 – 2.07; p = 0.02), but this correlation did not reach a statistical significance in multivariate analysis (HR = 1.37, 95% CI 0.98 – 1.92; p = 0.07). A higher LIPI was associated with a lower disease control rate in univariate (OR = 0.50, 95% CI 0.29 – 0.85; p = 0.01) and multivariate (OR = 0.55, 95% CI 0.31 – 0.98; p = 0.04) analyses. Conclusions: This study confirms the utility of the LIPI in prognostication and disease control prediction in advanced NSCLC patients treated with nivolumab in the second line of therapy or beyond.